Trefoil Therapeutics Partners With Price Vision Group for Patients with Corneal Endothelial Dystrophies
August 19, 2020 by Sam Ven1
Trefoil Therapeutics Begins First Clinical Trial at Price Vision Group for Patients with Corneal Endothelial Dystrophies
SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. To read the full press release, please click here.
September 9, 2020 at 2:07 pm
I am 70 years old with Fuch’s dystrophy and was referred to Dr. Stephen Johnson by Dr. David Box in October 2017 for a corneal transplant consultation. He advised an endothelial keratoplasty but the post treatment was lying flat on my back for 48 hours. I didn’t think I could do that. I am interested in your clinical trial (or future trials) for regenerative treatment. You actually performed a keratoplasty in 1991 with a follow up of a para plana vitrectomy in 1992 on my mother, Kathryn Stewart. I look forward to hearing from you.